Advertisement
Screener

ORAMED PHARMACEUTICALS INC. (ORMP) Graph

ORMP Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Cost of revenue (m); Research and development (m); Operating expenses (m).
  • 2026-03-31: Revenue (m); Cost of revenue (m); Research and development $1.59M; Operating expenses (m).
  • 2025-12-31: Revenue $0.00*; Cost of revenue $0.00*; Research and development $1.99M*; Operating expenses (m).
  • 2025-09-30: Revenue (m); Cost of revenue (m); Research and development $1.15M; Operating expenses (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)(m)(m)(m)$23.43M$78.16M
2026-03-31(m)(m)$1.59M(m)$11.13M$38.31M
2025-12-31$0.00*$0.00*$1.99M*(m)-$212.00K*(m)
2025-09-30(m)(m)$1.15M(m)$11.06M$48.40M
2025-06-30(m)(m)$1.03M(m)-$126.00K$13.29M
2025-03-31$2.00M$1.99M$2.21M(m)$584.00K-$7.64M
2024-09-30(m)(m)$2.24M(m)$1.13M-$19.62M
2024-06-30(m)(m)$1.44M(m)$1.63M$9.21M
2024-03-31(m)(m)$1.18M(m)(m)$1.54M
2023-09-30(m)(m)$957.00K(m)(m)-$3.22M
2023-06-30$674.00K(m)$1.82M(m)(m)-$1.19M
2023-03-31$666.00K(m)$4.43M(m)(m)-$3.40M
2022-09-30$682.00K(m)$5.35M(m)$100.00K-$7.06M
2022-06-30$674.00K(m)$9.18M(m)(m)-$10.53M
2022-03-31$666.00K(m)$5.84M$143.00K(m)-$10.71M
2021-11-30$674.00K(m)$6.41M$67.00K(m)-$8.10M
2021-09-30$682.00K(m)$6.09M(m)(m)(m)
2021-08-31$683.00K*(m)$5.84M*(m)(m)-$7.60M*
2021-06-30$674.00K(m)$3.20M(m)(m)-$3.91M
2021-05-31$681.00K(m)$5.50M(m)(m)-$5.21M
2021-03-31$666.00K(m)$6.17M$112.00K(m)-$6.06M
2021-02-28$665.00K(m)$3.87M(m)(m)-$4.61M
2020-11-30$674.00K(m)$5.77M$74.00K(m)-$5.57M
2020-05-31$681.00K(m)$1.93M(m)(m)-$2.28M
2020-02-29$674.00K(m)$3.32M(m)(m)-$3.69M
2019-11-30$674.00K(m)$2.02M(m)(m)-$2.54M
2019-05-31$682.00K(m)$3.86M(m)(m)$4.07M
2019-02-28$666.00K$55.00K$3.11M(m)-$300.00K$3.70M
2018-11-30$674.00K$35.00K$4.35M(m)(m)-$4.30M
2018-05-31$617.00K-$86.00K$4.19M(m)(m)-$4.35M
2018-02-28$604.00K(m)$2.72M(m)(m)-$2.92M
2017-11-30$611.00K(m)$2.33M(m)(m)-$2.53M
2017-05-31$617.00K(m)$2.27M(m)(m)-$1.97M
2017-02-28$611.00K(m)$3.13M(m)(m)-$3.18M
2016-11-30$610.00K$187.00K$2.35M(m)$400.00K-$2.64M
2016-05-31-$163.00K-$8.00K-$1.71M(m)(m)$2.00M
2016-02-29$125.00K$4.00K$1.30M(m)(m)-$1.82M
2015-11-30(m)(m)-$1.90M(m)(m)-$2.39M
2015-05-31(m)(m)$915.00K(m)(m)-$1.58M
2015-02-28(m)(m)$1.14M(m)(m)-$1.64M
2014-11-30(m)(m)$1.30M(m)(m)-$1.90M
2014-05-31(m)(m)-$1.09M(m)(m)$1.83M
2014-02-28(m)(m)$674.00K(m)(m)-$1.11M
2013-11-30(m)(m)$750.00K(m)(m)-$1.12M
2013-05-31(m)(m)$835.64K(m)(m)-$1.26M
2013-02-28(m)(m)$749.00K(m)(m)-$1.23M
2012-11-30(m)(m)$392.63K(m)(m)-$958.75K
2012-05-31(m)(m)$249.75K(m)(m)-$550.37K
2012-02-29(m)(m)$710.65K(m)(m)-$985.38K
2011-11-30(m)(m)$184.02K(m)(m)-$478.52K
2011-05-31(m)(m)$241.35K(m)(m)$457.37K
2011-02-28(m)(m)$341.33K(m)(m)-$642.79K
2010-11-30(m)(m)$286.49K(m)(m)-$602.78K

Revenue and expense 4 month

Period endRevenueResearch and developmentOperating expensesNet income
2022-12-31$904.00K$9.04M(m)(m)
2021-12-31$904.00K$9.04M$109.00K-$12.26M
2020-12-31$904.00K$6.89M$92.00K-$7.32M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)(m)$1.59M(m)$34.56M$116.47M
2025-06-30$2.00M$1.99M$3.24M(m)$458.00K$5.65M
2024-06-30(m)(m)$2.62M(m)$1.63M$10.75M
2023-06-30$1.34M(m)$6.25M(m)(m)-$4.59M
2022-06-30$1.34M(m)$15.02M$190.00K(m)-$20.96M
2021-06-30$1.34M(m)$9.37M$186.00K(m)-$9.97M
2021-02-28$1.34M(m)$9.64M(m)(m)-$10.18M
2020-02-29$1.35M(m)$5.34M(m)(m)-$6.23M
2019-02-28$1.34M$90.00K$7.46M(m)-$300.00K$8.00M
2018-02-28$1.22M(m)$5.05M(m)(m)-$5.45M
2017-02-28$1.22M$187.00K$5.48M(m)$400.00K-$5.82M
2016-02-29$125.00K$4.00K$3.20M(m)(m)-$4.21M
2015-02-28(m)(m)$2.44M(m)(m)-$3.53M
2014-02-28(m)(m)$1.42M(m)(m)-$2.24M
2013-02-28(m)(m)$1.14M(m)(m)-$2.18M
2012-02-29(m)(m)$894.66K(m)(m)-$1.46M
2011-02-28(m)(m)$627.82K(m)(m)-$1.25M

Revenue and expense 8 month

Period endRevenueResearch and development
2021-08-31$2.70M$20.99M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$2.00M$1.99M$4.39M(m)$11.52M$54.04M
2024-09-30(m)(m)$4.86M(m)$2.77M-$8.87M
2023-09-30$1.34M(m)$7.21M(m)(m)-$7.81M
2022-09-30$2.02M(m)$20.36M$201.00K$100.00K-$28.02M
2021-09-30$2.02M(m)$15.45M$198.00K(m)(m)
2021-05-31$2.02M(m)$15.14M(m)(m)-$15.38M
2020-05-31$2.03M(m)$7.27M(m)(m)-$8.52M
2019-05-31$2.02M$90.00K$11.32M(m)-$300.00K$12.07M
2018-05-31$1.83M-$86.00K$9.24M(m)(m)-$9.80M
2017-05-31$1.84M$187.00K$7.75M(m)$400.00K-$7.78M
2016-05-31-$288.00K-$12.00K-$4.91M(m)(m)$6.20M
2015-05-31(m)(m)$3.35M(m)(m)-$5.12M
2014-05-31(m)(m)-$2.51M(m)(m)$4.07M
2013-05-31(m)(m)$1.98M(m)(m)-$3.44M
2012-05-31(m)(m)$1.14M(m)(m)-$2.01M
2011-05-31(m)(m)$869.17K(m)(m)-$788.21K

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentIncome taxNet income
2025-12-31$2.00M$1.99M$6.38M$11.31M$75.32K
2024-12-31(m)(m)$6.32M$3.18M-$15.92K
2023-12-31$1.34M(m)$8.97M(m)$5.09K
2022-12-31$2.70M(m)$27.64M$100.00K-$36.56M
2021-08-31$2.70M(m)$20.99M(m)-$22.99M
2020-08-31$2.71M(m)$10.23M(m)-$11.51M
2019-08-31$2.70M$90.00K$13.52M$300.00K-$14.36M
2018-08-31$2.45M-$86.00K$11.98M(m)-$12.73M
2017-08-31$2.46M$187.00K$10.28M$400.00K-$10.48M
2016-08-31$641.00K$490.00K$7.71M$1.33M-$10.96M
2015-08-31(m)(m)$4.78M-$1.00K-$7.23M
2014-08-31(m)(m)$3.28M$4.00K-$5.70M
2013-08-31(m)(m)-$2.27M$205.00K$4.23M
2012-08-31(m)(m)$1.68M$90.00K-$3.34M
2011-08-31(m)(m)$1.16M-$23.98K-$1.56M
2010-08-31(m)(m)(m)(m)-$2.98M
2009-08-31(m)(m)(m)(m)-$2.76M
2008-08-31(m)(m)(m)(m)-$2.77M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B